Kyverna Therapeutics (KYTX) IPO Misrepresentation Case
$KYTX investors sued Kyverna Therapeutics for misleading them about clinical trial results and risks tied to its lead product, KYV-101.
On June 14, 2024, Kyverna revealed negative trial data at an industry conference, contradicting its earlier positive IPO statements. Following this news, $KYTX dropped by 25%
$KYTX investors can join this case to be notified about potential recovery.
Kyverna Therapeutics held its IPO on February 8, 2024, raising over $296 million by selling 14.5 million shares at $22 each. In its filings, the company highlighted early positive results from KYV-101 trials for lupus nephritis, showing improvements in urine protein creatinine ratio (UPCR).
However, Kyverna failed to disclose existing adverse trial data, including safety concerns and dose-limiting toxicities, misrepresenting the risks of KYV-101.
On June 14, 2024, at the European Alliance of Associations for Rheumatology conference, Kyverna revealed the adverse data.
By December 2024, $KYTX had fallen to $3.92, an 82% decline from its IPO price, as the withheld information came to light.
Based on these events, $KYTX investors filed a lawsuit against Kyverna Therapeutics, accusing the company of the following:
It misled investors by omitting adverse trial data from its IPO filings.
It failed to disclose risks associated with its lead product candidate, KYV-101.
Investors believe Kyverna misled them by withholding critical information about safety concerns and trial risks related to KYV-101.